Home Page Video Series 2 VL

REVIEW UroToday

Home Page Video Series 2 VL

Search

Evolving Landscape for Frontline Treatment in Clear Cell Metastatic Renal Cell Carcinoma - Toni K. Choueiri - Sumanta Kumar Pal Details In this conversation Toni Choueiri, MD, and Sumanta Kumar Pal, MD join Petros Grivas, MD, PhD reviewing the evolving landscape of metastatic renal cell carcinoma and highlight the trial design and the recently published CLEAR study. CLEAR is a phase 3 trial, that recruited patients with advanced renal cell carcinoma who had not received prior systemic therapy evaluating lenvatinib plus pembrolizum...
Efficacy by Duration or Number of Cycles of First-line Chemotherapy in the JAVELIN Bladder 100 Study - Petros Grivas Details Avelumab first-line maintenance therapy is approved in the United States for patients with advanced urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy based on significantly prolonged overall survival versus best supportive care alone. (median 21.4 months versus 14.3 months; HR 0.69, 95% CI 0.56-0.86) as reported in the phase III JAVELIN Bladder 100 trial...
Evaluating Circulating Tumor Cells in Patients on the CARD Trial - Eleni Efstathiou Details In the PHASE 4 CARD trial, cabazitaxel significantly improved radiographic progression-free survival (rPFS) and overall survival versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer who had received docetaxel and progressed within 12 months with the alternative androgen-signaling-targeted inhibitor. In this conversation, Alicia Morgans, MD, MPH, and E...
A New Standard of Care in Treatment of Advanced Urothelial Carcinoma from JAVELIN Bladder 100 - Cora Sternberg Details The analysis of the JAVELIN Bladder 100 trial, efficacy by duration or number of cycles of first-line chemotherapy presented at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) helped clinicians understand, the outcomes of avelumab from the JAVELIN 100 trial. The number of cycles (cycle every 3 weeks), of first-line chemotherapy. The optimal duration of firs...
Impact of Concomitant Prostate Cancer Therapy of Relugolix in Men with Advanced Prostate Cancer - Daniel J. George Details Daniel George, MD, and Neal Shore, MD, FACS, co-investigators of the Phase III HERO Trial join Alicia Morgans, MD, MPH recapping the 2021 GU ASCO analysis that Daniel George presented on the efficacy and safety of relugolix vs leuprolide in men with advanced prostate cancer. This was a subgroup analysis assessing the impact of concomitant prostate cancer therapy on the safety and efficacy of the o...
Sequential Radium-223 Treatment of mCRPC That Progressed After First-Line Novel Antihormonal Therapy, A Real-World Clinical Outcomes Study - Oliver Sartor Details Oliver Sartor, MD joins Alicia Morgans, MD, MPH to discuss a real-world clinical outcomes study of sequential novel antihormonal therapy (abiraterone or enzalutamide) or radium-223 (Ra-223) treatment of metastatic castration-resistant prostate cancer (mCRPC) that progressed after first-line NAH. This data is taken from the real world reports in the Flatiron Registry. Dr. Sartor presented this data...